Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-881 and HyQvia PK Study in Healthy Adults
NCT06895967Phase 1Completed
- Sponsor
- Takeda
- Start
- Mar 2025
- Primary completion
- Jul 2025
- Modality
- SC (Subcutaneous administration)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TAK-881 in primary immunodeficiency (PI) (2 arms), sponsored by Takeda. Primary endpoint: Baseline-corrected Area Under the Concentration-time Curve From Day 1 to Day 29 Based on Serum Total Immunoglobulin G (IgG) Levels. Started Mar 2025; status: completed.
02
Drugs
TAK-881
03
Conditions
primary immunodeficiency (PI)
Beyond the preview
Go deeper on NCT06895967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06895967.